GoldenGolden
Advanced Search
Compass Therapeutics

Compass Therapeutics

Compass Therapeutics is an antibody Therapies.

All edits

Edits on 13 Nov, 2021
Golden AI"Merge infobox in utils"
Golden AI edited on 13 Nov, 2021
Edits made to:
Infobox (+1/-1 properties)
Infobox
Competitors
Competitors
Biocytogen
Edits on 6 Jul, 2021
Aime Anne Nisay"Approved suggestion #1099924 from source: http://compasstherapeutics.com"
Aime Anne Nisay approved a suggestion from Golden's AI on 6 Jul, 2021
Edits on 7 Jun, 2021
Erin Scherfner"prospector:317:157221"
Erin Scherfner edited on 7 Jun, 2021
Edits made to:
Infobox (+3 properties)
Description (+18 characters)
Topic thumbnail

Compass Therapeutics

Antibody Therapies

Infobox
Edits on 5 Feb, 2021
Golden AI
Golden AI edited on 5 Feb, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Competitors
Edits on 1 Feb, 2021
Golden AI"prospector:137:67693"
Golden AI edited on 1 Feb, 2021
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 22 Jan, 2020
Meredith Hanel
Meredith Hanel edited on 22 Jan, 2020
Edits made to:
Infobox (+2 properties)
Article (+813 characters)
People (+1 rows) (+2 cells) (+41 characters)
Topic thumbnail

Compass Therapeutics

Antibody Therapies

Article

Compass Therapeutics develops antibody therapeutics that target the immune synapse for treatment of cancer. The immune synapse is the term for the molecular interactions which are part of an immune response which takes place in the gap between T cells and antigen presenting cells. Proper regulation ensures a balance where the host defends against pathogens and tumors and also does not develop autoimmunity. Compass Therapeutics is developing antibodies that engage T cells, NK cells and macrophages to promote tumor-specific activation or reverse immune suppression.

...

The company’s lead candidate as of 2020 was CTX-471, a fully human agonistic antibody of CD137 in clinical Phase 1 studies in patients with advanced solid tumors. Compass’s CTX-8371 drug in development is a novel PD-1/PD-L1 bispecific antibody.

People

Name
Role
LinkedIn

Thomas Schuetz, M.D., Ph.D

Co-Founder, CEO

Infobox
Industry
Edits on 20 Dec, 2019
Golden AI
Golden AI edited on 20 Dec, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 8 Jul, 2019
Golden AI"Remove default description"
Golden AI edited on 8 Jul, 2019
Edits made to:
Description (-7 characters)
Topic thumbnail

Compass Therapeutics

Company

Edits on 17 Apr, 2019
Golden AI
Golden AI edited on 17 Apr, 2019
Edits made to:
Description (+7 characters)
Topic thumbnail

Compass Therapeutics

Company

Edits on 7 Mar, 2019
Golden AI
Golden AI edited on 7 Mar, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 5 Mar, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 5 Mar, 2019
Edits made to:
Infobox (+2 properties)
Dawson Sewell"Initial topic creation"
Dawson Sewell created this topic on 5 Mar, 2019
Edits made to:
Topic thumbnail

 Compass Therapeutics

Antibody Therapies

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.